Celsus Therapeutics, a clinical-stage biotech developing novel anti-inflammatory synthetic drugs, filed on Thursday with the SEC to raise up to $12 million in an initial public offering. The London, United Kingdom-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CLTX. Celsus is currently traded on the OTC market under the symbol CLXSY. Oppenheimer & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
